|
Generics Lose as Court Protects Pfizer’s Lyrica Through 2018
Pfizer is trumpeting its exclusive rights to one of its best-selling products until late 2018 after a Delaware district court upheld its patents on pain and seizure drug Lyrica.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives